BBO-11818
[THERAPEUTIC_PROFILE]
KRAS mutant solid tumors
A small molecule protein degrader
[3D_INTERACTIVE_CONFORMATION]
[CLINICAL_TRIALS_REGISTRY]
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers
[INVESTIGATORS_&_FACILITY_ROSTER]
[PRIMARY_SUCCESS_ENDPOINTS]
Analysis Window: approximately 5 years
Analysis Window: approximately 5 years
[SECONDARY_SUCCESS_ENDPOINTS]
Analysis Window: approximately 5 years
Analysis Window: approximately 5 years
Analysis Window: approximately 5 years
Analysis Window: approximately 5 years
Analysis Window: approximately 5 years
Analysis Window: approximately 5 years
Analysis Window: approximately 5 years
Analysis Window: approximately 5 years
[COHORT_ARMS_ARCHITECTURE_BREAKDOWN]
Participants enrolled in this cohort will receive BBO-11818 as monotherapy
Participants enrolled in this cohort will receive BBO-11818 in combination with pembrolizumab infusion (IV)
Participants enrolled in this cohort will receive BBO-11818 in combination with pembrolizumab infusion (IV), cis/carboplatin infusion (IV), and pemetrexed infusion (IV)
Participants enrolled in this cohort will receive BBO-11818 in combination with cetuximab infusion (IV) with or without mFOLFOX6 infusion (IV)
Participants enrolled in this cohort will receive BBO-11818 in combination with BBO-10203 and mFOLFOX6 infusion (IV)
Participants enrolled in this cohort will receive BBO-11818 in combination with BBO-10203 and cetuximab infusion (IV)
Participants enrolled in this cohort will receive BBO-11818 in combination with cetuximab infusion (IV)
Participants enrolled in this cohort will receive BBO-11818 in combination with mFOLFIRINOX infusion (IV)
Participants enrolled in this cohort will receive BBO-11818 in combination with gemcitabine infusion (IV) and nab-paclitaxel infusion (IV)
Participants enrolled in this cohort will receive BBO-11818 in combination with BBO-10203
Participants enrolled in this cohort will receive BBO-11818 as monotherapy
Participants enrolled in this cohort will receive BBO-11818 in combination with pembrolizumab infusion (IV)
Participants enrolled in this cohort will receive BBO-11818 in combination with pembrolizumab infusion (IV), cis/carboplatin infusion (IV), and pemetrexed infusion (IV)
Participants enrolled in this cohort will receive BBO-11818 in combination with cetuximab infusion (IV) with or without mFOLFOX6 infusion (IV)
Participants enrolled in this cohort will receive BBO-11818 in combination with BBO-10203 and mFOLFOX6 infusion (IV)
Participants enrolled in this cohort will receive BBO-11818 in combination with BBO-10203 and cetuximab infusion (IV)
Participants enrolled in this cohort will receive BBO-11818 in combination with cetuximab infusion (IV)
Participants enrolled in this cohort will receive BBO-11818 in combination with mFOLFIRINOX infusion (IV)
Participants enrolled in this cohort will receive BBO-11818 in combination with gemcitabine infusion (IV) and nab-paclitaxel infusion (IV)
Participants enrolled in this cohort will receive BBO-11818 in combination with BBO-10203
[DOSING_&_INTERVENTION_SPECIFICITIES]
Participants will receive assigned dose of BBO-11818 orally (PO)
Patients will receive IV pembrolizumab
Patients will receive IV platinum chemotherapy (cisplatin or carboplatin)
Patients will receive IV pemetrexed
Patients will receive IV cetuximab
Patients may receive IV mFOLFOX6
Patients will receive IV mFOLFOX6
Participants will receive BBO-10203 orally (PO)
Patients will receive IV mFOLFIRINOX
Patients will receive IV gemcitabine
Patients will receive IV nab-paclitaxel